Successful treatment using agalsidase alfa of a patient with Fabry disease who had anaphylaxis after agalsidase beta: A case report


ÇAKMAK M. E.

Northern Clinics of Istanbul, cilt.11, sa.1, ss.88-90, 2024 (ESCI, Scopus, TRDizin)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 11 Sayı: 1
  • Basım Tarihi: 2024
  • Doi Numarası: 10.14744/nci.2022.45656
  • Dergi Adı: Northern Clinics of Istanbul
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.88-90
  • Anahtar Kelimeler: Agalsidase alfa, agalsidase beta, anaphylaxis, drug allergy, Fabry disease.
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Fabry disease is a rare genetic disease caused by a deficiency of α-galactosidase A gene (α-Gal A). Two intravenous enzymes administered every two weeks, agalsidase alfa and beta can slow disease progression and increase survival if administered early, before organ damage occurs. In this case report, we present a patient with a history of anaphylaxis to agalsidase beta who was successfully treated with agalsidase alfa.